OBJECTIVES: A significant number of children affected by congenital heart disease (CHD) develop heart failure early or late after surgery, and heart transplantation (OHTx) remains the last treatment option. Due to shortage of donor organs in paediatric group, mechanical circulatory support (MCS) is now routinely applied as bridging strategy to increase survival on the waiting list for OTHx. We sought to assess the impact of MCS as intention to bridge to OHTx in patients with CHD less than 16 years of age.
INTRODUCTION
Patients affected by congenital heart disease (CHD) can increasingly survive to adulthood due to improvements in surgical, cardiological and intensive care treatments [1] . A significant proportion develop heart failure either acutely or chronically after cardiac surgery [2] . Heart transplantation offers an improvement in survival to these patients. However, donor organ shortage remains a persistent and hitherto an insurmountable barrier [3] . Mechanical circulatory support (MCS) as bridge to transplantation offers a strategy to allow prolongation of window of opportunity to transplantation in this group. This has allowed more cardiac transplantations to be undertaken albeit with increased early morbidity and mortality [4] [5] [6] . However, this group still remains poorly studied with amalgamation of disparate categories such as dilated cardiomyopathies to confound the analysis. In addition, MCS for single ventricle also provides an increasingly challenging category [7] [8] [9] .
In order to define the feasibility of MCS in patients with CHD, we assessed our 15 years' institutional experience of congenital patients less than 16 years old receiving mechanical assist device for heart failure as bridge to transplantation, comparing the outcomes of biventricular and single-ventricle physiology.
METHODS
Institutional Review Board approval was obtained for the study and the board waived individual patient consent. The database of all patients less than 16 years of age who underwent MCS was retrospectively analysed and stratified by diagnosis. The bridge for transplantation programme at Freeman Hospital commenced in 1998. This has undergone transformation from an initial use of just venoarterial extracorporeal membrane oxygenator (VA ECMO) to the present use of Berlin Heart EXCOR device since 2005. Several combinations of various MCS strategies have been used including bridge-to-bridge strategy for the acutely ill child with initial resuscitation with VA ECMO and thereafter conversion to Berlin Heart for prolongation of support. Levitronix Centrimag® device has also been employed in some instances.
The National Health System in the UK has regionalized the care for children with end-stage heart failure to two centres, Freeman hospital being one of them. The use of mechanical support as bridge to transplantation and transplantation is exclusively undertaken in these centres. Accordingly, the majority of patients being treated at the Freeman hospital are tertiary referrals from other congenital cardiothoracic units: some of them electively for assessment and further management and some others in emergency, already on MCS after previous cardiac arrest requiring ECMO cardiopulmonary resuscitation.
Patients
Between January 1998 and September 2013, 106 patients received 113 episodes of MCS with paracorporeal devices as intention to bridge to transplantation. Of these, 29 patients had CHD as their primary diagnosis. Fifteen (52%) had biventricular circulation (Group A), while 14 (48%) had single-ventricular physiology (Group B). In the biventricular group, 5 children received VA ECMO, 6 left ventricular assist device (LVAD), 2 biventricular assist device (BIVAD), 1 VA ECMO followed by a BIVAD and 1 BIVAD followed by a VA ECMO (Table 1 ). In the single-ventricle group, 7 children were supported with VA ECMO, 2 with univentricular assist device (UVAD) and 4 with UVAD changed to VA ECMO; a child was surgically converted to a biventricular circulation and assisted with a BIVAD followed then by a VA ECMO (Table 2) .
Surgical strategies
ECMO was instituted via central cannulation (in case of failed weaning from cardiopulmonary bypass) or via neck vessel cannulation, initially using a roller pump and since 2010 the Levitronix Centrimag LVAS®. When used as second step after BIVAD or UVAD, ECMO was established using the Berlin Heart cannulas left in situ.
In particular instances, such as recurrent clot formation in the pulsatile devices or need to add an oxygenator in the circuit in case of lung dysfunction, the Berlin Heart pump was replaced with a continuous flow Levitronix Centrimag®, using the same cannulas.
In biventricular circulation, Berlin Heart EXCOR devices were implanted in routine position, with right atrial and pulmonary artery cannulas for the pulmonary (right) ventricle and with apical left ventricle and aortic cannulas for the systemic (left) ventricle.
In the setting of single-ventricle palliation, the surgical strategy to implant a Berlin Heart EXCOR device was adapted to the anatomical (situs, stage of palliation, multiple previous operation) and haemodynamic ( pulmonary vascular resistance, passive blood flow drainage in the lungs, presence of venovenous collaterals) variables. Five patients with failing bidirectional Glenn circulation were assisted with UVAD (apical and aortic cannulation) using larger size Berlin Heart ventricles to achieve successful haemodynamic support (Fig. 1) . In case of inadequate empting of the single ventricle, the option of switching the inflow cannula from the apex to the single atrium was considered. Coil embolization was applied in the presence of large venovenous collateral to achieve a better oxygen saturation. Finally, in case of recurrent hypoxia, persistent end-organ failure and inotropes dependency despite the UVAD support, elective conversion to venoarterial ECMO through the Berlin Heart cannulas was established. Of 2 children with failing first stage palliation (in the presence of modified Blalock-Taussig (BT) shunt), 1 was assisted with UVAD (apical and aortic cannulation) and the systemic-to-pulmonary artery shunt was reduced by narrowing the shunt to limit pulmonary blood flow (Fig. 2) . The other child was converted to a biventricular physiology, disconnecting the shunt, dividing the systemic venous return from the pulmonary venous return and creating a new chamber between the superior and the inferior venae cava. A BIVAD was then established with a right ventricle assist device through the new chamber and pulmonary artery, and an LVAD through the apex of the single ventricle and the aorta (Fig. 3) . The BIVAD was subsequently changed to a venoarterial ECMO.
Institutional protocol of care in ventricle assist device patients
Patients assisted with ventricular assist devices (VADs) (in form of Berlin Heart EXCOR and Levitronix Centrimag®) are not anticoagulated for 24-48 h to reduce excessive bleeding. Intravenous Heparin infusion is then started at 25 units/kg/h and continued during the time of MCS, keeping the anti-Xa levels between 0.35 and 0.7 units/ml. Once postoperative bleeding ceases, antiplatelet therapy is commenced, starting 1 mg/kg of Dypiridamole 6-hourly and thereafter adding Aspirin 1 mg/kg twice a day. A value of 7 g/l of haemoglobin is considered the threshold for institution of blood transfusion. Infection prophylaxis is continued for 48 h after the implantation using broad-spectrum antibiotics and antifungal drugs. Wound care consists of daily dressings using sterile saline 0.9% and avoiding alcoholic solutions. Once the drains are removed, the wound and cannula dressings are changed twice a week and swabs of the wound and of the cannula sites are sent once a week.
After implantation of MCS, all patients are listed for heart transplantation. However, an institutional protocol was established in order to allow recovery from VAD. During the implantation procedure, a left ventricle apical biopsy is performed to assess the degree of fibrosis and to achieve the correct diagnosis. In Berlin Heart EXCOR patients, the plan for potential recovery is based on weekly echocardiographic examination and, once a month, formal testing. This is undertaken with and without inotropic support. Echocardiographic, haemodynamic and biochemical examinations are undertaken at 10 min.
Clinical assessment
A retrospective cross-sectional clinical analysis was performed. Demographic and surgical variables were collected. All children were followed from the time of MCS implantation and censored at the time of recovery/explantation (removal from waiting list), death during support (death awaiting transplantation), transplantation leading to death before discharge and transplantation with survival to hospital discharge. Outcomes of biventricular and univentricular patients receiving MCS were compared in terms of major complications (renal support, chest exploration for bleeding and sepsis), survival to explantation/transplantation and survival to discharge. Major bleeding was considered an episode of haemorrhage requiring reoperation and blood transfusion; and sepsis was considered as evidence of systemic involvement by infection manifested by positive blood culture and/or hypotension [10] .
Statistical analysis
A descriptive statistical analysis was performed. Continuous data are presented as mean ±standard deviation, reporting confidence interval (CI) at 95%, and compared through the Student t-test. Categorical data are expressed as proportions and compared through the χ 2 test. All hypothesis tests used a 0.05 significance level. Analyses were performed using the STATA v 11.0 software.
RESULTS
Demographic characteristic of the population are reported in Table 3 . Children with univentricular physiology were younger at the time of MCS implantation, but not in a significant way. Age between 1 and 10 years was mostly represented in both groups, without significant differences comparing infants, bigger children and adolescents. The mean weight at time of circulatory support was similar in both groups. Tables 1 and 2 describe the demographic characteristics, the diagnosis, the MCS types and the outcome of each individual patient with biventricular and singleventricle physiology, respectively. In nearly 50% of the cases, with similar frequency in both groups, MCS was established after an episode of cardiac arrest requiring cardiopulmonary resuscitation. The mean overall length of support on the extracorporeal circulation was significantly longer in the biventricular group (P = 0.03), with a peak of 219 days in an infant on LVAD with Shone's complex and 61 days in a child after failing Glenn circulation. The duration of mechanical ventilation during MCS was similar in both groups. Clinical outcomes are reported in Table 4 . Morbidity and mortality of MCS for patients with single and biventricular circulation were compared. A greater proportion of patients with univentricular physiology required renal support during MCS (P = 0.03), with filter placement during venoarterial ECMO, peritoneal dialysis in the smallest children and continuous venovenous haemofiltration in the biggest. A significant number of new neurological events occurred in patients (6/15, 40%) with biventricular physiology on mechanical assist device (P = 0.04), this group had a significantly longer length of the paracorporeal support. Three of these children were in Berlin Heart LVAD: 1 had an embolic event during the 219 days (the longest in this series) of support before successful transplantation; 1 had a stroke at the time of VAD testing and was successfully explanted; 1 developed a neurological event because of recurrent clotting formation that required several Berlin Heart ventricles replacement and switching of the pulsatile circulation to a Levitronix Centrimag® machine with continuous flow. The incidence of tracheostomy for long-term ventilation, chest exploration for bleeding and sepsis did not differ significantly between the groups during MCS.
Five children successfully recovered after MCS, with explantation of the device (3 in the biventricular group and 2 in the single-ventricle group, P = NS). One child with two-ventricle physiology required a second run of MCS 1 year after explantation and died on the waiting list during support with Berlin Heart BIVAD. Eight patients, 4 per group, died during mechanical support (P = NS) and 16 patients, 8 per group, were successfully bridge to transplantation (P = NS). Two infants in the biventricular group required a second run of MCS after transplantation for acute graft failure: 1 died after 29 days of Berlin Heart BIVAD for multiorgan failure and 1 was supported for 5 days on ECMO and then successfully retransplanted. In the single-ventricle group, 1 patient had an unsuccessful second run of MCS (ECMO) after transplantation.
The overall survival to recovery/transplantation of MCS in paediatric congenital heart patients was 72% and the overall survival to discharge was 59%. Both, survival to recovery/transplantation (73 vs 71%, P = NS) and survival to discharge (60 vs 57%, P = NS) did not differ significantly when comparing the biventricular and the single-ventricle physiology, respectively.
All children surviving to hospital discharge are alive at an average follow-up of 4.5 ± 3.4 years.
DISCUSSION
The improvement in survival following cardiac surgery for the treatment of congenital heart surgery is a modern day success story [1] . This has, however, generated an increasing number of patients who develop heart failure either acutely or chronically. These patients would ultimately require transplantation for either improvement in quality-of-life or survival [11] . Since the successful use of ECMO for respiratory support, it was just a matter of time before this modality would be used to support this group of patient to transplantation. We first used ECMO to successfully bridge to transplantation in 1998. However, it soon became clear that most of the patients would require cardiac support longer than could be achieved with ECMO. This came in the form of Berlin Heart EXCOR, which was first implanted in 1990 [12] . Since then, with improvement in Berlin Heart technology, implantation techniques and anticoagulation management, there have been several reports of good medium-term support with this device [4] [5] [6] . In addition, Berlin Heart has been shown to be superior to ECMO in length and quality of support [10] . However, this prolonged support is not without an increase in morbidity [5, 6] .
Berlin Heart has been predominantly used in patients with myocardial disease and there are only a few reports of its use in patients with CHD [4] [5] [6] . This is not surprising due to a higher mortality and morbidity associated with its use in this group [13, 14] . However, in a recent paper reviewing the US use of Berlin Heart EXCOR by Almond et al. [6] , there was no increased risk with the usage of Berlin Heart. Similarly, the use of ECMO prior to insertion of the Berlin Heart was also not a risk factor in the entire cohort. We also found similar results in our overall experience with paediatric MCS [5] .
The use of MCS in single-ventricle support still remains a challenge. This is due to complex anatomy coupled with competing physiological demands. Not surprisingly, there are only a few reports in the literature of use of MCS in this group [8, 9] . In patients with Fontan completion our approach has been to undertake ECMO support. This has been a successful strategy for us due to the urgent allocation system for heart transplantation in the UK, which preferentially allocates hearts to the paediatric patients from adult donors. These patients are older and have larger body weight making them suitable for this strategy. However, there have been recent reports of successful LVAD support using a HeartMate device [15] and Berlin Heart [16] in patients who previously had a failing Fontan circulation.
Our strategy in supporting patients with failing bidirectional cavopulmonary connection has evolved over time [9] . These were due to a complex set of interaction between ventricular dysfunction and altered pulmonary resistance. Our initial problems were related to placement of a ventricular chamber commensurate with the body weight recommendation by the Berlin Heart group. But we felt that a larger chamber was required to provide a larger cardiac output than the prescribed size could provide. However, in some patients we found worsening of lung function after an apparent satisfactory initial result from the Berlin Heart insertion, resulting in hypoxia, ventilator dependency and ongoing inotropic support. This necessitated changing these patients to VA ECMO support but still continuing to use the Berlin Heart cannulas, thus essentially converting them to centrally cannulated ECMO. Using this modality, we were able to successfully transplant a patient in semielective condition after extubation on ECMO (Patient 5 in Table 2 ). In 1 child with progressive heart failure after Norwood palliation, and severe tricuspid regurgitation and high pulmonary vascular resistance, we tried an experimental approach separating the circulation and using a BIVAD: the pulmonary venous return was separated from the systemic venous return and the superior vena cava (SVC) and inferior vena cava (IVC) were joined together with a 14 mm Dacron tube, the shunt was ligated, a 10 ml Berlin Heart pulsatile pump was implanted with the inflow cannula placed in the artificial connection between the SVC and IVC and the outflow cannula in the pulmonary arteries and another 10 ml Berlin Heart ventricle was implanted inserting the apical cannula in right ventricle and the outflow cannula in the Damus-Kaye-Stansel anastomosis (Fig. 3) . The child remained in BIVAD Berlin Heart for 13 days, requiring numerous ventricle changes: for that reason, the MCS was switched to a BIVAD using Levitronix Centrimag for 5 days and subsequently switched to a venoarterial ECMO due to inadequate systemic oxygenation and impaired lung function. In spite of our unsuccessful attempt, we feel that this approach could work in patients with elevated pulmonary vascular resistance.
Single-ventricle support with VAD remains a challenging group; we only had limited success in this group. The patients undergoing successful transplantation in this cohort were lucky to have received a donor organ in a relatively short period. We feel the complex anatomical and physiological nature of failing single ventricle was not conducive to longer support. This is evident in our experience where we had to switch the modality of support to cope with increasingly difficult haemodynamic conditions. Morbidity represents a significant problem in patients requiring MCS for CHD. Patients with single ventricle were particularly prone to renal replacement support (P = 0.03). This is not surprising as this is the sickest of the sick group. The management of anticoagulation therapy again remains problematic, since the right equilibrium between clotting and bleeding is difficult to achieve. Despite a meticulous approach to the latter, the number of cerebrovascular events still bedevils the outcomes of children undergoing MCS, representing the leading cause of death in most of the series [4] [5] [6] . We found a significant incidence of new neurological events in the biventricular group (P = 0.04). This is perhaps due to longer length of support required in this group compared with the patients with single ventricles (P = 0.03).
The present clinical experience suggests that children with CHD supported with mechanical assist devices for acute or end-stage heart failure can be satisfactorily bridged to heart transplantation despite the significant cumulative morbidity. Nearly two-third of them survive to discharge after transplantation. Most importantly, single-ventricle when compared with the biventricular circulation does not increase the risk for death before transplantation and hospital discharge. 
